2017.10.10
FY02/2018 Q2 Results Earnings Release Presentation
2017.09.25PDF( 63KB)
Notification of the commencement of the Phase II clinical study of Investigational HP-5000 in the USA (an analgesic transdermal drug)
2017.08.31PDF( 62KB)
Notification of submission of supplemental new drug application (NDA) for the addition of a new 0.5mg dose of the transdermal, long-action pain relief patch FENTOS® TAPE (development code:HFT-290)
2017.08.08PDF(128KB)
Announcement of Establishment of New Company
2017.07.18PDF(175KB)
Notification o f the commencement of the Phase III clinical study of HP-3150 in in Japan for "cancer pain" (an algesic transdermal drug containing NSAIDs)